In the early 1980s the discovery and isolation of a new lipid mediator, platelet activating factor (PAF), led to a lot of activity and excitement in the inflammation world. PAF, which is a family of structurally related ether-linked phospholipids, is formed from the action of phospholipase A2 and acetyltransferase on membrane alkylacyl phospholipids. PAF was found to possess many properties that made it well suited as a proinflammatory mediator of inflammation in many inflammatory diseases. Interest in its potential role as a mediator of asthma was fuelled by the observations that it induced airway microvascular leakage, bronchoconstriction, and bronchial hyper-responsiveness. In addition, PAF could activate a wide variety of cells including neutrophils, eosinophils, and endothelial cells, and was also found to have potent chemotactic properties for eosinophils. With the discovery of PAF receptor antagonists, the hypothesis that PAF was involved in chronic asthma was tested. In two studies of moderate to severe asthmatic patients no positive clinical benefit was demonstrated with two different PAF receptor antagonists, casting doubt on the contribution of PAF to the pathophysiology of chronic asthma despite the fact that PAF or its metabolite or precursor, lysophosphatidylcholine (lyso-PAF), is released in the airways of patients with asthma. It has been argued that the potency of the receptor antagonists may not have been adequate in the in vivo situation, or these antagonists may not be blocking the effects of other bioactive PAF homologues acting perhaps at different PAF receptor subtypes. A preliminary study performed in Japan indicated that a higher dose of one of the two antagonists used, WEB 2086, provided some benefit in steroid-dependent asthmatic patients. However, enthusiasm for studying PAF antagonists in asthma has waned. Despite this, further interesting observations continue to be reported, particularly with relation to its potential role in asthma, including the paper published by Shindo et al in this issue of Thorax.

Degradation of PAF

Being a potent bioactive mediator, it makes sense that PAF can be degraded rapidly by PAF acetylhydrolase which would therefore limit the activity of PAF. A decrease in PAF acetylhydrolase activity would lead to greater inflammatory responses induced by endogenously released PAF. Recent studies in Japan have examined the presence of respiratory symptoms in asthmatic children and the activity of serum PAF acetylhydrolase. These investigators found that 4% of a healthy Japanese population had a deficiency of this enzyme and that, amongst asthmatic children, the severity of symptoms was greater in those with PAF acetylhydrolase deficiency. More recently, the inherited serum PAF acetylhydrolase deficiency was found to be the result of a point mutation in exon 9 which leads to complete abolition of enzymatic activity. Whether these individuals are more prone to inflammatory conditions such as asthma can only be determined by prospective studies. Perhaps of more relevance is whether this deficiency could lead to more severe asthma in asthmatic patients.

Proinflammatory effects of PAF

The study by Shindo and colleagues further extends the well known proinflammatory effects of PAF. They have found that PAF can prime neutrophils from asthmatic patients, but not from normal volunteers, to release more products of 5-lipoxygenase (5-LO) – namely LTB4 and 5-HETE – when these cells are activated by calcium ionophore. Shindo et al propose that this priming effect on 5-LO activity is secondary to the enhancement of calcium influx by PAF, but there were no differences in PAF-induced production of LTB4 between normal and asthmatic neutrophils. It is of interest that preincubation of neutrophils with granulocyte-macrophage colony-stimulating factor (GM-CSF) can enhance the ability of PAF to stimulate leukotriene synthesis by increasing both arachidonic acid availability and 5-lipoxygenase activity. Thus, a priming effect of GM-CSF on neutrophils which in turn primes the effects of PAF is plausible and would represent a real cascade effect on the final neutrophil response. IgE-dependent release of LTC4 and histamine from human basophils is also enhanced by PAF after preincubation with GM-CSF. Shindo et al have also previously shown that

PAF and ventilation-perfusion distribution

Rodríguez-Roisin and colleagues have recently extended the effects of PAF in man by studying its actions on pulmonary gas exchange. In both normal and asthmatic subjects inhaled PAF induced small falls in arterial PO2, with more profound changes in arterial-alveolar PO2 that were entirely caused by ventilation-perfusion (V/Q) mismatch. The pattern of V/Q mismatch was similar to that commonly found in patients with acute severe asthma, which has led to the hypothesis that PAF could underlie the hypoxaemia seen in this condition. Acute severe asthma is also characterised by intense oedema and mucus plugging which could be initiated by PAF. PAF-induced ventilation-perfusion mismatch was not related to airway constriction because changes in pulmonary resistance induced by PAF were rather small and larger degrees of bronchoconstriction induced by methacholine did not cause much V/Q imbalance. These abnormalities in V/Q could have resulted from alterations in microvascular exudation of plasma in the small airways induced by PAF.
PAF primes LTC₄ release from stimulated eosinophils from asthmatic patients.¹³

These observations, coupled with the results of the present study, indicate that PAF may play an amplifying role in the chronic inflammatory process of asthma by acting on many cell types. It remains to be explained why the clinical studies with PAF receptor antagonists have not shown major clinical benefit for asthmatic patients when reasonable bioactive levels of PAF and lyso-PAF can be detected in patients with chronic asthma.¹³¹⁵ Continuing interest in the actions and mechanisms of action of PAF may give further insight into this question.

K F CHUNG
National Heart and Lung Institute
at Imperial College School of Medicine
and Royal Brompton Hospital,
London SW3 6LY, UK